CEL-SCI Quarterly Patient Enrollment In Its Head And Neck Cancer Phase III Trial Increases Eight Fold Over Same Prior Year Period

CEL-SCI Corporation (NYSE MKT:

) today announced that during the past three months it has enrolled 58 patients with advanced primary, not yet treated, head and neck cancer into its global pivotal Phase III head and neck cancer trial for its investigational immunotherapy Multikine* (Leukocyte Interleukin, Injection). This quarterly enrollment represents a more than eight fold increase in enrollment compared to the same September to November quarter in 2013 when seven patients were enrolled. This brings the total number of patients enrolled in the Phase III study to about 310. "During 2013 we had to dismiss Inventiv Clinical, LLC, the prior clinical research organization (CRO) running our Phase III study, for, among other things, lack of patient enrollment in the study. We hired two new companies in Inventiv's place. As can be clearly seen from the rapid increase in enrollment under the new companies, the study is now proceeding quite well. Yet we are working to further increase enrollment with the aim of fully enrolling all patients by the end of 2015. Almost every month we are adding new clinical centers to the study," stated CEL-SCI Chief Executive Officer Geert Kersten. A total of 880 patients are expected to be enrolled, through over 100 clinical centers in over 20 countries. Twenty patients were enrolled in the study in November 2014.